A phase II trial of active specific immunotherapy in patients with indolent lymphoma using autologous lymphoma-derived heat shock protein-peptide complex (HSPPC-96) [cancer vaccine HSPPC-96]
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vitespen (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 08 Nov 2005 New trial record.